Correlation between paraproteinaemia and viral reactivation after allo-SCT

Patrizia Chiusolo, Luca Laurenti, Federica Sora', Paola Cattani, Rosaria Santangelo, Simona Sica, Elisabetta Metafuni, Sabrina Giammarco, Silvia Bellesi, Stefania Manzara, Giuseppe Leone

Research output: Contribution to journalArticle

1 Citation (Scopus)


Medd et al.,1 retrospectively studied the occurrence of paraproteinaemia after allo-SCT in a cohort of 91 patients. They detected a paraproteinaemia incidence of 32%, multiple in the majority of cases, with a predominance of an IgG isotype and with equal kappa/lambda restriction. In this report, the most important risk factor for the development of post-transplant paraproteinaemia was CMV reactivation, which was more frequent when alemtuzumab was included in conditioning regimen. The authors also described a poorer OS in patients with paraproteinaemia, with relapse being the commonest cause of death in this group of patients. None of the patients with paraproteinaemia subsequently developed myeloma or a lymphoproliferative disorder and only one patient developed cryoglobulinemia.
Original languageEnglish
Pages (from-to)1-1
Number of pages1
JournalBone Marrow Transplantation
Publication statusPublished - 2012


  • ebv
  • paraproteinemia


Dive into the research topics of 'Correlation between paraproteinaemia and viral reactivation after allo-SCT'. Together they form a unique fingerprint.

Cite this